|
WO2021067744A1
|
|
Chemical modifications of small interfering rna with minimal fluorine content
|
|
WO2021041756A1
|
|
Ligand-2'-modified nucleic acids, synthesis thereof and intermediate compounds thereof
|
|
WO2020226960A1
|
|
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
|
WO2020206350A1
|
|
Compositions and methods for inhibiting gene expression in the central nervous system
|
|
WO2020167593A1
|
|
Methods and compositions for inhibiting expression of cyp27a1
|
|
WO2020139764A1
|
|
Compositions and methods for inhibiting hmgb1 expression
|
|
WO2020123083A1
|
|
Double-stranded nucleic acid inhibitor molecules containing a triloop
|
|
AU2019252529A1
|
|
Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides
|
|
EP3765611A1
|
|
Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
|
|
WO2019168686A1
|
|
Methods and compositions for treating bile duct paucity-associated conditions
|
|
EP3740247A1
|
|
Compositions and methods for inhibiting gys2 expression
|
|
AU2019209324A1
|
|
Compositions and methods for inhibiting ALDH2 expression
|
|
CN111587116A
|
|
Decreasing beta-catenin and IDO expression to boost immunotherapy
|
|
CN111372593A
|
|
Method of treating hepatitis B infection
|
|
KR20200078538A
|
|
Beta catenin nucleic acid inhibitor molecule
|
|
CN111448319A
|
|
Methods and compositions for inhibiting expression of L DHA
|
|
EP3645013A1
|
|
Compositions and methods for inhibiting hmgb1 expression
|
|
CA3057679A1
|
|
Reducing beta-catenin expression to potentiate immunotherapy
|
|
AU2017321892A1
|
|
4'-phosphate analogs and oligonucleotides comprising the same
|
|
MX2019002075A
|
|
Compositions comprising reversibly modified oligonucleotides and uses thereof.
|
